Ray Therapeutics

Ray Therapeutics is pioneering the application of optogenetics to treat blindness caused by retinal degeneration. The company's platform aims to bypass defunct photoreceptors by making surviving inner retinal neurons light-sensitive, offering a potential one-time treatment for a range of inherited and age-related retinal diseases. With its lead candidate, RTx-015, in clinical development for retinitis pigmentosa, Ray is building a seasoned leadership team to advance its pipeline. The company represents a convergence of gene therapy and neuromodulation, targeting a significant unmet medical need in ophthalmology.

Optogenetic gene therapy platform using viral vectors to deliver light-sensitive opsins to surviving retinal neurons, reprogramming them to function as surrogate photoreceptors and restore vision in degenerative retinal diseases.

Ray Therapeutics competes in the emerging field of optogenetic vision restoration with companies like GenSight Biologics (GS030) and Bionic Sight. It also faces indirect competition from traditional gene replacement therapies (e.g., Spark Therapeutics) for specific mutations earlier in disease, and from the newly approved complement inhibitors for Geographic Atrophy (Apellis, Iveric Bio), which slow progression but do not restore vision.